v3.25.4
Borrowings (Details)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended 17 Months Ended 18 Months Ended
Dec. 29, 2021
shares
Dec. 31, 2023
EUR (€)
Dec. 31, 2021
EUR (€)
Dec. 31, 2021
USD ($)
Aug. 31, 2020
EUR (€)
tranche
shares
Jul. 31, 2020
USD ($)
tranche
Dec. 31, 2023
EUR (€)
Dec. 31, 2025
EUR (€)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
EUR (€)
Dec. 29, 2021
EUR (€)
shares
Dec. 29, 2021
USD ($)
shares
Dec. 31, 2024
EUR (€)
Dec. 31, 2019
EUR (€)
Dec. 10, 2018
EUR (€)
Disclosure of detailed information about borrowings [line items]                                
Total borrowings               € 4,872,000           € 4,582,000    
Current portion               4,872,000           4,582,000    
Gains on waiver of convertible debt                 € 1,866,000              
Innovation credit                                
Disclosure of detailed information about borrowings [line items]                                
Total borrowings               2,899,000           2,899,000    
Accrued interest               1,973,000           1,683,000    
RVO innovation credit for cystic sepofarsen program [Member]                                
Disclosure of detailed information about borrowings [line items]                                
Current portion               € 2,899,000           € 2,899,000    
Notional amount                               € 3,907,000
Repayment of borrowings             € 1,008,000                  
Conditional waiver of debt including accrued interest   € 4,292,000                            
Convertible Debt | Maximum                                
Disclosure of detailed information about borrowings [line items]                                
Number of shares exercisable for issued warrants | shares         302,676                      
Convertible loans Amylon Therapeutics B.V.                                
Disclosure of detailed information about borrowings [line items]                                
Notional amount                             € 2,300,000  
Gains on waiver of convertible debt                 € 1,866,000 € 1,144,000            
Interest rate (as percent)                             8.00%  
Convertible Debt Pontifax Medison and Kreos Capital Debt Financing                                
Disclosure of detailed information about borrowings [line items]                                
Interest rate (as percent) 8.20%                     8.20% 8.20%      
Warrants, economic lifetime               5 years                
Convertible Debt Pontifax Medison Debt Financing                                
Disclosure of detailed information about borrowings [line items]                                
Notional amount | $           $ 30.0                    
Proceeds from borrowings                       € 8,400,000 $ 10.0      
Number of tranches | tranche           3                    
Maximum borrowing capacity per tranche | $           $ 10.0                    
Term of debt           54 months                    
Debt, interest only payment term           24 months                    
Convertible Debt Kreos Capital Debt Financing                                
Disclosure of detailed information about borrowings [line items]                                
Notional amount         € 15,000,000                      
Proceeds from borrowings                     € 5,000,000          
Number of tranches | tranche         3                      
Maximum borrowing capacity per tranche         € 5,000,000                      
Term of debt         54 months                      
Debt, interest only payment term         24 months                      
Convertible Debt Pontifax Medison and Kreos Capital Debt Financing, amended agreement                                
Disclosure of detailed information about borrowings [line items]                                
Proceeds from borrowings     € 26,500,000 $ 30.0                        
Term of debt 54 months                              
Debt, interest only payment term 33 months                              
Number of tranches from original agreement replaced with amendment agreement 2                              
Convertible Debt Pontifax Medison and Kreos Capital Debt Financing, amended agreement | Maximum                                
Disclosure of detailed information about borrowings [line items]                                
Number of shares exercisable for issued warrants | shares 376,952                     376,952 376,952